New oral anticoagulants vs. Warfarin treatment: No need for pharmacogenomics?

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 1, 2014, Pages 17-19

  Baker, W L ^a   Chamberlin, K W ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DABIGATRAN; FRESH FROZEN PLASMA; MULTIDRUG RESISTANCE PROTEIN; PROTHROMBIN COMPLEX; RIVAROXABAN; VITAMIN K EPOXIDE REDUCTASE; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TRANSPORT; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENOMICS; PRIORITY JOURNAL; PROMOTER REGION; RACEMIC MIXTURE; REVIEW; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FACTOR XA; GENOTYPE; HUMANS; MORPHOLINES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THIOPHENES; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84902681532     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.48     Document Type: Review

References (10)

1. You, J.J. et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141, e531S-e575S (2012)
2. Baker, W.L., Cios, D.A., Sander, S.D. & Coleman, C.I. Meta-Analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J. Manag. Care. Pharm. 15, 244-252 (2009)
3. Ageno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M. & Palareti, G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141, e44S-e88S (2012)
4. Johnson, J.A. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011)
5. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009)
6. Anderson, J.L. et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563-2570 (2007)
7. Holbrook, A. et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidencebased clinical practice guidelines. Chest 141, e152S-e184S (2012)
8. Pirmohamed, M. et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369, 2294-2303 (2013)
9. Kimmel, S.E. et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369, 2283-2293 (2013)
10. Baker, W.L. & Phung, O.J. Systematic review and adjusted indirect comparison meta-Analysis of oral anticoagulants in atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes. 5, 711-719 (2012)